Search by Drug Name or NDC
NDC 00005-2000-02 Prevnar 20 2.2; 2.2; 2.2; 2.2; 2.2; 2.2; 2.2; 2.2; 2.2; 2.2; 2.2; 2.2; 2.2; 2.2; 2.2; 2.2; 4.4; 2.2; 2.2; 2.2 ug/.5mL; ug/.5mL; ug/.5mL; ug/.5mL; ug/.5mL; ug/.5mL; ug/.5mL; ug/.5mL; ug/.5mL; ug/.5mL; ug/.5mL; ug/.5mL; ug/.5mL; ug/.5mL; ug/.5mL; ug/.5mL; ug/.5mL; ug/.5mL; ug/.5mL; ug/.5mL Details
Prevnar 20 2.2; 2.2; 2.2; 2.2; 2.2; 2.2; 2.2; 2.2; 2.2; 2.2; 2.2; 2.2; 2.2; 2.2; 2.2; 2.2; 4.4; 2.2; 2.2; 2.2 ug/.5mL; ug/.5mL; ug/.5mL; ug/.5mL; ug/.5mL; ug/.5mL; ug/.5mL; ug/.5mL; ug/.5mL; ug/.5mL; ug/.5mL; ug/.5mL; ug/.5mL; ug/.5mL; ug/.5mL; ug/.5mL; ug/.5mL; ug/.5mL; ug/.5mL; ug/.5mL
Prevnar 20 is a INTRAMUSCULAR INJECTION, SUSPENSION in the VACCINE category. It is labeled and distributed by Wyeth Pharmaceutical Division of Wyeth Holdings LLC. The primary component is STREPTOCOCCUS PNEUMONIAE TYPE 1 CAPSULAR POLYSACCHARIDE DIPHTHERIA CRM197 PROTEIN CONJUGATE ANTIGEN; STREPTOCOCCUS PNEUMONIAE TYPE 10A CAPSULAR POLYSACCHARIDE DIPHTHERIA CRM197 PROTEIN CONJUGATE ANTIGEN; STREPTOCOCCUS PNEUMONIAE TYPE 11A CAPSULAR POLYSACC.
Product Information
| NDC | 00005-2000 |
|---|---|
| Product ID | 0005-2000_48ecccfb-5879-4dc7-8016-551e4e1dfec1 |
| Associated GPIs | 1720006540E620 |
| GCN Sequence Number | 082386 |
| GCN Sequence Number Description | pneumoc 20-val conj-Dip crm/PF SYRINGE 0.5 ML INTRAMUSC |
| HIC3 | W7L |
| HIC3 Description | GRAM POSITIVE COCCI VACCINES |
| GCN | 49791 |
| HICL Sequence Number | 047431 |
| HICL Sequence Number Description | PNEUMOCOCCAL 20-VALENT CONJUGATE VACCINE (DIPHTHERIA CRM)/PF |
| Brand/Generic | Brand |
| Proprietary Name | Prevnar 20 |
| Proprietary Name Suffix | n/a |
| Non-Proprietary Name | Pneumococcal 20-valent Conjugate Vaccine |
| Product Type | VACCINE |
| Dosage Form | INJECTION, SUSPENSION |
| Route | INTRAMUSCULAR |
| Active Ingredient Strength | 2.2; 2.2; 2.2; 2.2; 2.2; 2.2; 2.2; 2.2; 2.2; 2.2; 2.2; 2.2; 2.2; 2.2; 2.2; 2.2; 4.4; 2.2; 2.2; 2.2 |
| Active Ingredient Units | ug/.5mL; ug/.5mL; ug/.5mL; ug/.5mL; ug/.5mL; ug/.5mL; ug/.5mL; ug/.5mL; ug/.5mL; ug/.5mL; ug/.5mL; ug/.5mL; ug/.5mL; ug/.5mL; ug/.5mL; ug/.5mL; ug/.5mL; ug/.5mL; ug/.5mL; ug/.5mL |
| Substance Name | STREPTOCOCCUS PNEUMONIAE TYPE 1 CAPSULAR POLYSACCHARIDE DIPHTHERIA CRM197 PROTEIN CONJUGATE ANTIGEN; STREPTOCOCCUS PNEUMONIAE TYPE 10A CAPSULAR POLYSACCHARIDE DIPHTHERIA CRM197 PROTEIN CONJUGATE ANTIGEN; STREPTOCOCCUS PNEUMONIAE TYPE 11A CAPSULAR POLYSACC |
| Labeler Name | Wyeth Pharmaceutical Division of Wyeth Holdings LLC |
| Pharmaceutical Class | Actively Acquired Immunity [PE], Actively Acquired Immunity [PE], Actively Acquired Immunity [PE], Actively Acquired Immunity [PE], Actively Acquired Immunity [PE], Actively Acquired Immunity [PE], Actively Acquired Immunity [PE], Actively Acquired Immuni |
| DEA Schedule | n/a |
| Marketing Category | BLA |
| Application Number | BLA125731 |
| Listing Certified Through | 2024-12-31 |
Package
NDC 00005-2000-02 (00005200002)
| NDC Package Code | 0005-2000-02 |
|---|---|
| Billing NDC | 00005200002 |
| Package | 1 SYRINGE in 1 CARTON (0005-2000-02) / .5 mL in 1 SYRINGE (0005-2000-01) |
| Marketing Start Date | 2021-08-10 |
| NDC Exclude Flag | N |
| Pricing Information | N/A |